NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
Key Highlights
- ➤NervGen appoints Sam Jackson, MD, MBA, as Chief Medical Officer
- ➤Jackson will lead execution of the ongoing Phase 3 RESTORE study
- ➤RESTORE is expected to enroll approximately 150 participants across the United States and Canada
- ➤NVG‑291 targets chronic traumatic cervical motor-incomplete spinal cord injury
- ➤NVG‑291 has FDA Breakthrough Therapy and Fast Track designations
Expert Statements
Adam Rogers, President and Chief Executive Officer of NervGen
“Sam is an accomplished physician-scientist and proven drug developer with expertise in innovative neuroscience trial design and experience advancing therapies through pivotal development and approval”
Adam Rogers, President and Chief Executive Officer of NervGen
“We are thrilled to welcome him to NervGen as we continue to strengthen our organization, advance through late-stage development and seek to realize the potential of NVG‑291 as a pipeline-in-a-product.”
Adam Rogers, President and Chief Executive Officer of NervGen
“Sam will be instrumental in shaping our strategy for additional indications and strengthening our execution of RESTORE to deliver what could be the first therapy to enable the nervous system to repair itself.”
Sam Jackson, Chief Medical Officer of NervGen
“NervGen’s novel approach to overcoming the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs) with a subcutaneously administered therapy is very exciting, and the findings from the Phase 1b/2a CONNECT SCI study reinforce my confidence in NVG‑291’s transformative potential for people living with spinal cord injury and other forms of nervous system damage”
Sam Jackson, Chief Medical Officer of NervGen
“I look forward to advancing NVG-291 through RESTORE toward potential regulatory approval and realizing its broader potential across additional indications associated with CSPG upregulation.”
* Dr. Jackson brings expertise in innovative neuroscience trial design, leading pivotal Phase 3 studies and supporting FDA approval * He will lead execution of the ongoing Phase 3 RESTORE study and support clinical expansion of NVG‑291 as a potential pipeline-in-a-product MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Sam Jackson, MD, MBA, as Chief Medical Officer. Dr. Jackson will work alongside the Chief Executive Officer and Board of Directors to shape and execute the Company’s clinical development strategy.
Dr. Jackson has extensive experience in designing and executing clinical trials in neuroscience, most recently in cervical dystonia, Parkinson’s disease, Alzheimer’s disease and frontotemporal dementia. He has led clinical teams, designed cutting-edge clinical trials, built development organizations and contributed to regulatory submissions resulting in FDA approval.
Get started
Create a free account to read the full story.
